Loading Events

« All Events

Medicon Village Academy: Drug Development – Serendipity or Science

October 6 @ 12:30 - 17:00

Medicon Village Academy – an educational meeting concept for sharing life science knowledge

Drug development is a challenging journey, we will discuss questions you may not even consider asking. In this seminar, highly experienced people from the life science industry will share their successes, failures and insights on how we can develop great innovations into medicines. SDS and Medicon Village welcome you to an engaging afternoon.

Click here for more information and registration»

Programme

12.30-13.00 Lunch.
13.00-13.05 Welcome note. Susanna Dahlgren, SDS Regional Director, Lund.
13.05-14.00 Drug Development – Serendipity or Science. Keynote speaker: Johan Luthman, EVP & Head R&D Lundbeck.
14.00-14.30 How to increase probability of success in drug discovery projects? Reflections by a chemist. Johan Evenäs, CEO RedGlead Discovery.
14.30-15.00 Coffee break.
15.00-15.30 More right & less wrong – in a shorter time. Ulrika Axelsson, Business Coach Smile Incubator.
15.30-16.00 Cantargia – building a late clinical stage Biotech company from a novel molecular target. Göran Forsberg, CEO Cantargia.
16.00-16.30 Development of combination- and borderline products – Challenges and Opportunities. Anna-Karin Alm, CEO SDS MedteQ.
16.30-17.00 Panel discussion and concluding remarks.
17.00 After Work networking hosted by SDS Life Science.

 

Medicon Village Academy is an educational meeting concept for sharing life science knowledge. This time the event is organized in collaboration with SDS Life Science and SDS MedteQ.

Venue

Bistro Merge
IDEON Science Park logo

Keep track of future developments with the Ideon newsletter!

You can unsubscribe in one click and we will never share your email address with third parties.

You have Successfully Subscribed!

IDEON Science Park logo

KEEP TRACK OF FUTURE DEVELOPMENTS WITH THE IDEON NEWSLETTER!

You can unsubscribe in one click and we will never share your email address with third parties.

You have Successfully Subscribed!

Share This